Prokinetic Agents for Gastroparesis
Gastroparesis is delayed gastric emptying in the absence of mechanical obstruction, most classically in long-standing diabetics who lose effective gastric contraction. Prokinetic agents accelerate gastric emptying and are a core part of management alongside dietary modification and glycemic control. The three agents to know—metoclopramide, erythromycin, and domperidone—each work through a distinct receptor mechanism and carry a distinct limiting drawback.
Metoclopramide
Metoclopramide is a dopamine D2 receptor antagonist with additional 5-HT4 agonist activity. This combined action improves gastric emptying, making it a first-line prokinetic in gastroparesis. Its key hazard is tardive dyskinesia—a potentially irreversible movement disorder that limits long-term or high-dose use. Because it is centrally penetrating, it also carries other CNS/extrapyramidal risks. On exam, pair 'prokinetic + tardive dyskinesia' directly with metoclopramide.
Erythromycin
Erythromycin acts as a motilin receptor agonist, stimulating gastric contractions and accelerating emptying. Its major limitation is tachyphylaxis—the therapeutic effect diminishes with continued use—which restricts its role largely to short-term or acute situations rather than chronic maintenance therapy. Recognize erythromycin as the macrolide antibiotic repurposed for its motilin-agonist prokinetic effect.
Domperidone
Domperidone is a peripheral D2 antagonist that reaches only negligible concentrations in the CNS—it does cross the blood-brain barrier to a minimal degree, but is actively pumped back out by P-glycoprotein, so central effects are far less than with metoclopramide. This makes it attractive when central side effects must be avoided, but it is not FDA approved in the US, limiting its availability. Its main teaching point is the contrast with metoclopramide: same D2 antagonism, but with minimal effective CNS penetration. Note it can prolong the QT interval.
Refractory Disease and Adjuncts
When prokinetics and dietary measures fail, options include nutritional support with a venting gastrostomy and/or feeding jejunostomy, gastric electrical stimulation ('gastric pacemaker'), and surgical approaches such as pyloroplasty, gastrojejunostomy, or (rarely) subtotal gastrectomy. Pyloric botulinum toxin injection has been used but is NOT recommended for routine use—randomized trials show no benefit over placebo. Above all, optimizing glycemic control in diabetics is the single most impactful step, since acute hyperglycemia itself delays gastric emptying.
High-yield
- Gastroparesis = delayed gastric emptying without mechanical obstruction; diabetics are the classic patients.
- Metoclopramide = D2 antagonist + 5-HT4 agonist; watch for tardive dyskinesia.
- Erythromycin = motilin receptor agonist; tachyphylaxis limits long-term use.
- Domperidone = peripheral D2 antagonist with negligible CNS penetration (P-glycoprotein efflux at the BBB); fewer CNS effects, not FDA approved in the US, can prolong QT.
- In diabetic gastroparesis, optimizing glycemic control can be the single most impactful intervention because acute hyperglycemia independently delays gastric emptying.
- Dietary strategy: small, frequent, low-fat, low-fiber meals; liquid meals may be better tolerated.
- Pyloric botulinum toxin injection is NOT supported by randomized trials and is not recommended for routine use.
Pitfalls
- Do not attribute tardive dyskinesia to erythromycin or domperidone—it is the metoclopramide-associated adverse effect.
- Do not expect erythromycin to work well for chronic maintenance; tachyphylaxis undermines long-term efficacy.
- Forgetting that domperidone is a D2 antagonist just like metoclopramide—the difference is CNS penetration, not receptor target.
- Saying domperidone completely fails to cross the blood-brain barrier—it crosses minimally but is effluxed by P-glycoprotein, giving negligible CNS levels.
- Reaching for prokinetics before optimizing glucose in a diabetic; hyperglycemia perpetuates delayed emptying.
- Assuming domperidone is a readily available US option—it is not FDA approved in the US.
- Listing pyloric botulinum toxin as an effective refractory therapy—trials show no benefit over placebo.
Clinical pearls
- Metoclopramide's dual D2-antagonist/5-HT4-agonist action also gives it antiemetic utility.
- Erythromycin's prokinetic effect is a receptor 'side effect' (motilin agonism) of an antibiotic.
- Domperidone's negligible CNS penetration—due to P-glycoprotein efflux at the BBB—is its main advantage over metoclopramide.
- Chronic hyperglycemia contributes to vagal nerve damage, worsening the gastroparesis cycle over time.
Frequently asked
Why is metoclopramide not ideal for long-term use in gastroparesis?
Because it carries a risk of tardive dyskinesia. As a centrally penetrating D2 antagonist, prolonged or high-dose exposure can produce this potentially irreversible movement disorder, limiting chronic use.
How does erythromycin improve gastric emptying?
It acts as a motilin receptor agonist, stimulating gastric contractions. However, tachyphylaxis—loss of effect over time—limits its usefulness for long-term therapy.
What distinguishes domperidone from metoclopramide?
Both are D2 antagonists, but domperidone reaches only negligible CNS concentrations—it crosses the blood-brain barrier minimally and is actively effluxed by P-glycoprotein—so it produces fewer central side effects. The trade-offs are that it can prolong the QT interval and is not FDA approved in the US.
In a diabetic with poorly controlled glucose and gastroparesis, what is the most impactful first step?
Optimize glycemic control. Acute hyperglycemia independently delays gastric emptying, creating a vicious cycle, so improving glucose can significantly relieve symptoms even before adding prokinetics.
What dietary modifications help gastroparesis?
Small, frequent, low-fat, low-fiber meals; avoiding fatty and high-fiber foods that delay emptying; and liquid meals, which may be better tolerated.
Which prokinetic mechanism should you match to each drug?
Metoclopramide = D2 antagonist plus 5-HT4 agonist; erythromycin = motilin receptor agonist; domperidone = peripheral D2 antagonist with negligible CNS penetration.
What options exist for refractory gastroparesis beyond medications?
Options include nutritional support (venting gastrostomy and/or feeding jejunostomy), gastric electrical stimulation ('gastric pacemaker'), and surgical approaches such as pyloroplasty, gastrojejunostomy, or rarely subtotal gastrectomy. Pyloric botulinum toxin injection is not recommended for routine use because randomized trials have shown no benefit over placebo.
Turn this into reasoning you can use on exam day — practice Prokinetic Agents for Gastroparesis on branching cases where your decisions shape the patient.